Drugs / ARQ 621
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00825487 | Aug 2009 → May 2011 | neoplasm | ArQule, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARQ 621 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00825487 ↗ |
| Modality | Small molecule | — CHEMBL4303449 ↗ |
| Route | Intravenous | “intravenous ARQ 621 administered” NCT00825487 ↗ |